Monday November 30, 2020 21:09

Heathcare Press Release : 06 Nov 2020

Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to Heathcare—06 Nov 20

Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.[i] The STEP 3